REPLIGEN CORP Convertible Notes Payable, Current
REPLIGEN CORP (RGEN) had Convertible Notes Payable, Current of $0 as of 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2025-03-14
- 2024-12-31: Convertible Notes Payable, Current $0.00.
- 2024-09-30: Convertible Notes Payable, Current $0.00.
- 2024-06-30: Convertible Notes Payable, Current $69.48M.
- 2024-03-31: Convertible Notes Payable, Current $69.48M.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-14 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-18 |
| 2024-06-30 | $69.48M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $69.48M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $69.45M 10-K · filed 2025-03-14 |
| 2023-09-30 | $285.96M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $285.52M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $285.07M 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $284.62M 10-Q/A · filed 2024-11-18 |
| 2022-09-30 | $284.17M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $283.71M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $283.27M 10-Q · filed 2022-04-27 |
| 2022-01-01 | $27.60M 10-K · filed 2023-02-22 |
| 2021-12-31 | $255.26M 10-K · filed 2023-02-22 |
| 2021-09-30 | $252.32M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $249.42M 10-Q · filed 2021-07-27 |
| 2021-03-31 | $246.56M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $243.74M 10-K · filed 2022-02-17 |
| 2019-06-30 | $105.70M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $104.59M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $103.49M 10-K · filed 2020-02-26 |
| 2018-09-30 | $102.40M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $101.33M 10-Q · filed 2018-08-02 |
| 2017-09-30 | $98.23M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |